Cargando…
Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis
INTRODUCTION: Rational selection of disease modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis (RA) has many potential advantages, including rapid disease control, reduced long-term disability and reduced overall cost to the healthcare system. Inter-individual genetic difference...
Autores principales: | Wiese, Michael D, Schnabl, Matthew, O'Doherty, Catherine, Spargo, Llewellyn D, Sorich, Michael J, Cleland, Leslie G, Proudman, Susanna M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580556/ https://www.ncbi.nlm.nih.gov/pubmed/22784880 http://dx.doi.org/10.1186/ar3911 |
Ejemplares similares
-
Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients
por: Hopkins, AM, et al.
Publicado: (2015) -
Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years
por: Wabe, Nasir, et al.
Publicado: (2015) -
Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis
por: Brown, Zoe, et al.
Publicado: (2020) -
Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2020) -
Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs
por: Daraghmeh, Dala N, et al.
Publicado: (2022)